# Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)

> **NCT02980991** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 80 (actual)

## Conditions studied

- Lung Adenocarcinoma

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02980991
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-01
- **Final completion:** 2018-04
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980991, "Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02980991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*